CLRB
Cellectar Biosciences, Inc.
Next earnings Aug 12, 2026 · consensus $-0.41 EPS
Last earnings +8.8% on 2026-05-14
$2.52
▲ 0.00%$2.52▼ -71.21%
over 1Y
L $2.23EODHDH $9.70
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W-1.9%
1M-19.7%
3M-6.7%
YTD-27.4%
1Y-71.2%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Conservative balance sheet (liabilities/equity 0.59x).
Cellectar Biosciences, Inc. shows limited reported revenue, and -255.2% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$24.1M | -$28.8M | -$39.0M | -$51.8M | -$23.0M |
| Net income | -$24.1M | -$28.6M | -$42.8M | -$44.6M | -$21.8M |
| Diluted EPS | -$4.35 | -$4.05 | -$3.50 | -$41.89 | -$8.35 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$2.18M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-203.9%
FCF yield-216.4%
Quality & risk
ROIC (est.)-204.7%
Free cash flow-$23.1M
Total debt$330K
Net cash$12.9M
Piotroski F-Score3/7
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY-90.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — restated periodic report (2026-04-30). Worth a closer look.
- S-1/A Securities registration2026-05-29
- DEF 14A Proxy statement2026-05-28
- S-1 Securities registration2026-05-19
- 8-K Officer / director change2026-05-18
- 8-K Earnings results2026-05-14
- 10-Q Quarterly report2026-05-14
- 8-K Material agreement2026-05-08
- 10-K/A Restated periodic report2026-04-30
- 8-K Earnings results2026-03-04
Recent filings
all on EDGAR ↗3Period ending 2026-05-182026-06-09open ↗SCHEDULE 13GFiling2026-06-05open ↗424B3Filing2026-06-02open ↗EFFECTFiling2026-06-01open ↗S-1/AFiling2026-05-29open ↗DEFA14AFiling2026-05-28open ↗DEF 14APeriod ending 2026-07-072026-05-28open ↗S-1Filing2026-05-19open ↗PRE 14APeriod ending 2026-05-182026-05-18open ↗8-KPeriod ending 2026-05-172026-05-18open ↗8-KPeriod ending 2026-05-142026-05-14open ↗10-QPeriod ending 2026-03-312026-05-14open ↗
Frequently asked
- Is Cellectar Biosciences, Inc. (CLRB) a buy?
- CLRB currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.59x).
- What is Cellectar Biosciences, Inc.'s quality score?
- CLRB scores 59.15384615384615/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001279704, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 8:09:40 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.